| Similar Articles |
|---|
 |
The Motley Fool
April 14, 2008
Brian Lawler |
PDL BioPharma's Split Decision PDL BioPharma is finally taking further steps to try to realize better value for the different parts of its business.   |
The Motley Fool
April 28, 2011
Brian Orelli |
Buying Royalty Streams on the Cheap If management can't do it, PDL Biopharma's investors are in trouble. The trick is to find patents that are secure and a royalty stream that's predictable. |
The Motley Fool
September 24, 2007
Brian Lawler |
Seismic Shifts at PDL No matter what its hedge fund owner, Third Point, decides it wants to do with PDL, one thing is clear: A year from now, PDL BioPharma will not be the same drugmaker that it is today. Investors, take note. |
The Motley Fool
May 30, 2008
Brian Lawler |
PDL Shakeup Lifts Shares Shares of PDL BioPharma rise after a longtime board member, currently the company's interim CEO, departs. |
The Motley Fool
July 9, 2004
Charly Travers |
Protein Design Labs' Windfall Royalties from Genentech could mean big things for PDL. |
The Motley Fool
February 6, 2008
Brian Lawler |
PDL BioPharma Regroups, Piece by Piece The company still brings in plenty of money, despite selling off assets. Investors, take note. |
The Motley Fool
March 15, 2005
Charly Travers |
PDL Eyeing Up Profits A timely acquisition is paying off for this drug maker. Investors, take note. |
The Motley Fool
December 7, 2011
Dan Caplinger |
Has PDL BioPharma Become the Perfect Stock? Having moved from special dividends to a pure regular-dividend payout has improved income visibility for shareholders. |
The Motley Fool
February 27, 2007
Brian Lawler |
PDL Keeps Us Waiting PDL BioPharma announces its year-end financial results. Investors, take note. |
The Motley Fool
September 26, 2007
Brian Lawler |
Shareholders Pile On Against PDL Another large shareholder has come out against the status quo at PDL BioPharma. Management resignations seen as necessary by those wanting to sell or break apart the biopharma. |
The Motley Fool
March 5, 2008
Brian Lawler |
PDL Taken Off the Block Yesterday, PDL BioPharma announced that it had failed to find an acquirer; instead, it will launch another round of restructuring. |
The Motley Fool
December 16, 2011
Brian Orelli |
Biotech Royalties, Almost as Good as Cash They're flexible, and all royalties have value. |
The Motley Fool
August 18, 2008
Brian Lawler |
When Breaking Up Isn't Hard to Do PDL BioPharma and Enzon are the latest biotechs looking to spin off parts of their business. |
The Motley Fool
December 18, 2007
Brian Lawler |
PDL Liquidation Sale Begins PDL BioPharma's sale of a chemotherapy drug indicates it could recoup what it paid for ESP Pharma. Investors, take note. |
The Motley Fool
August 5, 2005
Charly Travers |
No Surprise Over PDL's Upside Protein Design Labs' overwhelmingly positive earnings release is good news for shareholders. |
The Motley Fool
December 13, 2004
Charly Travers |
PDL Rakes It In A robust revenue stream combined with an exciting drug pipeline is this biotech's recipe for success. |
The Motley Fool
August 2, 2007
Brian Lawler |
PDL Minds Its Mild Manners The biopharma announces placid second-quarter results -- investors, take note. |
The Motley Fool
November 6, 2006
Brian Lawler |
Mixed Feelings About PDL The biopharmaceutical's third-quarter results look fine on the surface, but does deeper digging reveal some reasons for investors to be concerned? |
The Motley Fool
August 29, 2007
Brian Lawler |
PDL Lands in a Hazard The biopharma announces a dramatic shift following the failure of its lead drug. Shares of PDL are down only 19% this morning, presumably because the thought of a leaner and thriftier PDL with its royalty-generating potential is a welcome relief to some investors. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Protein Design Labs is a great company for biotech investors. It has a diverse and growing revenue stream, will turn cash-flow positive next year, and has some potential winners in its pipeline to increase the company's value for long-term-minded shareholders. |
The Motley Fool
November 2, 2004
Charly Travers |
Just the Medicine for PDL Losses are shrinking as drug royalties spur strong revenue growth. |
The Motley Fool
May 7, 2008
Brian Lawler |
PDL Delivers a Dividend The drugmaker's investors get a hefty payout. |
The Motley Fool
September 28, 2007
Brian Lawler |
Interview With PDL Co-Founder Cary Queen PDL BioPharma has generated much investor activism against its current management team, with some investors calling for a sale of the drugmaker. In this interview, co-founder Cary Queen discusses the current state of affairs. |
The Motley Fool
January 26, 2005
Charly Travers |
Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock. |
The Motley Fool
March 16, 2007
Brian Lawler |
PDL's Friend Comes Through PDL and partner Biogen advance one of their lead drug candidates. Investors, take note. |
The Motley Fool
October 15, 2007
Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool
April 27, 2007
Brian Lawler |
PDL Gets the Go-Ahead Signal The biopharma moves its lead compound into phase 3 testing. Investors, take note. |
The Motley Fool
February 1, 2008
Brian Lawler |
Alexion Looks for a Bigger Niche Alexion Pharmaceutical announces sales of its rare blood disorder medication should expand in 2008. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. |
Chemistry World
February 27, 2013
Andrew Turley |
Talk of a $6.6bn deal for Elan Irish drug maker Elan has been surprised by a potential $6.6 billion offer being mooted by investment firm Royalty Pharma. |
The Motley Fool
May 26, 2009
Brian Orelli |
Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake. |
The Motley Fool
August 21, 2008
Brian Lawler |
PDL BioPharma's Partnership Makes Sense Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer. |
The Motley Fool
August 3, 2005
Charly Travers |
Biotech's Big Deal The market is pleased with the partnership between Protein Design Labs and Biogen IDEC. |
The Motley Fool
November 27, 2006
Brian Lawler |
Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note. |
The Motley Fool
August 21, 2007
Brian Lawler |
Change of Pace at PDL Shares of PDL BioPharma have risen more than 10% since CEO McDade announced yesterday that he would resign by the end of the year. |
The Motley Fool
May 3, 2005
Charly Travers |
PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner. |
The Motley Fool
August 22, 2006
Brian Lawler |
Sticking With Myriad Genetics The potential for growth in one division offsets the risk in its trials for an Alzheimer's drug. For less risk-adverse investors, the 5% pullback in Myriad's shares Tuesday might offer a great chance to invest in this well-run company. |
The Motley Fool
July 26, 2006
Brian Lawler |
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. |
The Motley Fool
May 5, 2006
Stephen D. Simpson |
Biogen Idec Needs a Booster Tysabri had better come back strong, or growth could come up short for this biotech. Investors, take note. |
The Motley Fool
October 13, 2010
Jordan DiPietro |
3 Sinking Stocks for Savvy Investors These three socks may be ready to climb. |
The Motley Fool
July 27, 2007
Brian Lawler |
Millennium Waits for the Future Millennium Pharmaceutical has eleven new drugs in the pipeline for the future, but for today all they have is lower revenue and higher expenditure guidance. |
The Motley Fool
August 4, 2004
Charly Travers |
Labs' Report Offers Mixed Results TProtein Design Labs' royalty intake looks great, but its drug development does not. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Biotech Frankenstock Investors, here is the perfect biotechnology beast. Cephalon... Roche... Exelixis... etc. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
January 29, 2008
Brian Lawler |
Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected. |
The Motley Fool
August 10, 2010
Charly Travers |
PDL BioPharma's Magic Formula If you want low-fuss investing options that aren't mutual funds or exchange-traded funds, you should consider a mechanical investing strategy. See how it works with this BioPharma stock. |
The Motley Fool
March 15, 2007
Brian Lawler |
Dueling Fools: Elan Bear Rebuttal With so many risks and unknowns embedded in Tysabri, investors should not be convinced Elan can provide a miracle. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
The Motley Fool
July 10, 2008
Brian Lawler |
Seattle Genetics Has What Others Want Out-licensing its platform technology could mean big bucks. |
